Madison Vaccines Incorporated’s clinical trial for metastatic prostate cancer is expanding to the University of Washington, its third site, the company announced recently.

According to a release, MVI-118 is being explored for use in combination with androgen deprivation therapy to delay resistance and prolong duration of disease control in men with metastatic prostate cancer.

“Reimbursement potential is always part of our strategy,” MVI CEO Richard Lesniewski said in a statement. “Developing agents with low costs of goods, that use simple delivery mechanisms, is critical to the long-term success of immune activating agents as affordable and sustainable therapies.”

The Phase 1 clinical study is already taking place at the University of Wisconsin and the Rutgers Cancer Institute.